BR0203172A - Agentes terapêuticos para acondroplasia - Google Patents

Agentes terapêuticos para acondroplasia

Info

Publication number
BR0203172A
BR0203172A BR0203172-8A BR0203172A BR0203172A BR 0203172 A BR0203172 A BR 0203172A BR 0203172 A BR0203172 A BR 0203172A BR 0203172 A BR0203172 A BR 0203172A
Authority
BR
Brazil
Prior art keywords
therapeutic agents
achondroplasia
fgfr3
mutations
achondroplasia caused
Prior art date
Application number
BR0203172-8A
Other languages
English (en)
Other versions
BRPI0203172B1 (pt
BRPI0203172B8 (pt
Inventor
Kazuwa Nakao
Original Assignee
Kazuwa Nakao
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP2001301586A external-priority patent/JP2003104908A/ja
Priority claimed from JP2001310322A external-priority patent/JP4252746B2/ja
Application filed by Kazuwa Nakao filed Critical Kazuwa Nakao
Publication of BR0203172A publication Critical patent/BR0203172A/pt
Publication of BRPI0203172B1 publication Critical patent/BRPI0203172B1/pt
Publication of BRPI0203172B8 publication Critical patent/BRPI0203172B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"AGENTES TERAPêUTICOS PARA ACONDROPLASIA". A presente invenção visa fornecer novos agentes terapêuticos para acondroplasia causada por mutações em FGFR3. São divulgados agentes terapêuticos para acondroplasia causada pela inibição de crescimento da cartilagem resultante de mutações no gene para o receptor do fator de crescimento de fibroblasto 3 (FGFR3), que compreende uma substância que ativa a guanilil ciclase B (GC-B) como um ingrediente ativo.
BRPI0203172A 2001-09-28 2002-08-13 composição farmacêutica para acondroplasia BRPI0203172B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001301586A JP2003104908A (ja) 2001-09-28 2001-09-28 軟骨無形成症治療剤
JP2001310322A JP4252746B2 (ja) 2001-10-05 2001-10-05 軟骨無形成症治療剤

Publications (3)

Publication Number Publication Date
BR0203172A true BR0203172A (pt) 2003-09-09
BRPI0203172B1 BRPI0203172B1 (pt) 2016-02-23
BRPI0203172B8 BRPI0203172B8 (pt) 2021-05-25

Family

ID=26623312

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0203172A BRPI0203172B8 (pt) 2001-09-28 2002-08-13 composição farmacêutica para acondroplasia

Country Status (3)

Country Link
US (2) US6743425B2 (pt)
BR (1) BRPI0203172B8 (pt)
CA (2) CA2398030C (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL142118A0 (en) * 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
US8137397B2 (en) * 2004-02-26 2012-03-20 Boston Scientific Scimed, Inc. Medical devices
EP1743653A4 (en) * 2004-03-31 2009-09-30 Kazuwa Nakao COMPOSITION FOR INCREASING BODY SIZE
CN1960758B (zh) * 2004-03-31 2014-10-22 中外制药株式会社 关节炎的治疗剂或预防剂
EP1759001B1 (en) 2004-04-21 2011-04-13 Enobia Pharma Inc. Bone delivery conjugates and method of using same to target proteins to bone
ES2278519B1 (es) * 2005-09-02 2008-09-16 Fundacion Magar Tratamiento de la acondroplasia por la administracion de dinucleotidos.
JP2011504506A (ja) * 2007-11-21 2011-02-10 バイオマリン ファーマシューティカル インコーポレイテッド Ｃ型ナトリウム利尿ペプチドの変異体
KR102225470B1 (ko) 2009-05-20 2021-03-10 바이오마린 파머수티컬 인크. 씨형 나트륨이뇨 펩티드의 변이체
WO2011153531A1 (en) 2010-06-04 2011-12-08 University Of South Florida Method of treating skeletal dysplasias using vessel dilator
CA2823066A1 (en) 2010-12-27 2012-07-05 Alexion Pharma International Sarl Compositions comprising natriuretic peptides and methods of use thereof
CA2852874A1 (en) 2011-10-19 2013-04-25 Alexion Pharma Holding Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
WO2013088191A1 (en) 2011-12-12 2013-06-20 Institut National De La Sante Et De La Recherche Medicale (Inserm) Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
KR20160002681A (ko) 2013-01-16 2016-01-08 인썸(인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰메디칼르) 골격 성장 지연 질환의 예방 또는 치료에 사용하기 위한 용해성 섬유아세포 성장 인자 수용체 3(fgr3) 폴리펩티드
ES2529369B2 (es) * 2013-07-09 2015-10-14 Ocupharm Diagnostics S.L. Uso del compuesto 2,5-dihidroxibencenosulfonato de calcio (calcio dobesilato) para la elaboracion de un medicamento para el tratamiento de la acondroplasia
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
MX2017007392A (es) 2014-12-05 2019-01-24 Alexion Pharma Inc Tratamiento de convulsiones con fosfatasa alcalina recombinante.
JP6868561B2 (ja) 2015-01-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼ欠損を有する被験者を治療する方法
AU2016308624B2 (en) 2015-08-17 2022-06-23 Alexion Pharmaceuticals, Inc. Manufacturing of alkaline phosphatases
JP6868617B2 (ja) 2015-09-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 低ホスファターゼ血症の組織非特異的アルカリホスファターゼ（ｔｎｓａｌｐ）酵素補充療法に有効な投薬計画の特定
EP3368062A4 (en) 2015-10-30 2019-07-03 Alexion Pharmaceuticals, Inc. METHODS OF TREATING CRANIOSYNOSTOSIS IN A PATIENT
EP3400065A1 (en) 2016-01-08 2018-11-14 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with reduced side-effects
AU2017205693B2 (en) 2016-01-08 2022-03-31 Ascendis Pharma Growth Disorders A/S Controlled-release CNP agonists with low initial NPR-B activity
KR20180100624A (ko) 2016-01-08 2018-09-11 아센디스 파마 그로우쓰 디스오더스 에이/에스 증가된 nep 안정성을 갖는 제어 방출성 cnp 작용제
KR102373744B1 (ko) 2016-01-08 2022-03-15 아센디스 파마 그로우쓰 디스오더스 에이/에스 낮은 npr-c 결합을 갖는 제어 방출성 cnp 작용제
CA3007979C (en) 2016-01-08 2023-12-19 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with carrier attachment at the ring moiety
US11065306B2 (en) 2016-03-08 2021-07-20 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
EP3436052A4 (en) 2016-04-01 2019-10-09 Alexion Pharmaceuticals, Inc. TREATMENT OF MUSCLE WEAKNESS USING ALKALINE PHOSPHATASES
EP3436020A4 (en) 2016-04-01 2019-12-25 Alexion Pharmaceuticals, Inc. METHOD FOR TREATING HYPOPHOSPHATASIE IN TEENS AND ADULTS
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
MX2018016257A (es) 2016-07-07 2019-11-21 Therachon Sas Polipéptidos del receptor 3 del factor de crecimiento de fibroblastos solubles (sfgfr3) y usos de los mismos.
US11116821B2 (en) 2016-08-18 2021-09-14 Alexion Pharmaceuticals, Inc. Methods for treating tracheobronchomalacia
SG10202111952PA (en) 2016-09-29 2021-12-30 Ascendis Pharma Growth Disorders As Combination therapy with controlled-release cnp agonists
EP3600383A4 (en) 2017-03-31 2020-10-28 Alexion Pharmaceuticals, Inc. METHODS FOR TREATMENT OF HYPOPHOSPHATASIA (HPP) IN ADULTS AND ADOLESCENTS
EP3773684A1 (en) 2018-03-30 2021-02-17 Alexion Pharmaceuticals, Inc. Manufacturing of glycoproteins
JP2020015733A (ja) * 2019-08-19 2020-01-30 アンセルムＩｎｓｅｒｍ 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体３（ｆｇｒ３）ポリペプチド
EP4291224A1 (en) 2021-02-12 2023-12-20 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5352770A (en) 1990-04-20 1994-10-04 Hisayuki Matsuo Porcine derived novel physiologically active peptide
JP2930380B2 (ja) 1990-07-13 1999-08-03 壽之 松尾 ブタ由来新規生理活性ペプチド（ｃｎｐ―５３）
JP2977158B2 (ja) 1990-09-07 1999-11-10 壽之 松尾 トリ由来新規生理活性ペプチド（ニワトリｃｎｐ）
JP2977159B2 (ja) 1990-09-07 1999-11-10 壽之 松尾 カエル由来新規生理活性ペプチド（カエルｃｎｐ）
JP3026354B2 (ja) 1990-09-27 2000-03-27 壽之 松尾 ヒトｃｎｐ遺伝子及び前駆体蛋白
JP2809533B2 (ja) 1991-01-31 1998-10-08 壽之 松尾 Ｃｎｐ類似体ペプチド
EP1159423B1 (en) * 1998-10-08 2005-03-09 The University of Hong Kong Uses of transgenic animals containing a type x collagen mutant
IL142118A0 (en) 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias

Also Published As

Publication number Publication date
BRPI0203172B1 (pt) 2016-02-23
CA2398030A1 (en) 2003-03-28
US6743425B2 (en) 2004-06-01
US20040198665A1 (en) 2004-10-07
CA2398030C (en) 2016-05-24
CA2918219A1 (en) 2003-03-28
US20030068313A1 (en) 2003-04-10
BRPI0203172B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
BR0203172A (pt) Agentes terapêuticos para acondroplasia
TR200102967T2 (tr) Substitüsyonlu azollar
BR0208150A (pt) Antagonistas de mch e sua aplicação no tratamento da obesidade
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
ATE248837T1 (de) Chinuclidin-acrylamide
DK0853083T3 (da) Pyridylfuran- og piridylthiophenforbindelser og farmaceutisk anvendelse deraf
MY128654A (en) Liquid pharmaceutical composition containing an erythropoietin derivative
IL178128A0 (en) Salts of 3-0-(3',3'-dimethyl-succinyl) betulinic acid and pharmaceutical compositions containing the same
BR0210028A (pt) Agentes antibacterianos
BR0010524A (pt) Tratamento de tumores humanos refratários com antagonistas de receptor de fator de crescimento epidérmico
BR0312421A (pt) Uso de inibidores de cept e opcionalmente inibidores hmg coa redutase e/ou agentes anti-hipertensivos
UY26851A1 (es) Derivados de la 4-fenilpiridina
MXPA05007609A (es) Antagonista de un receptor sensible al calcio.
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
BR0009472A (pt) Antagonistas de lhrh com propriedades desolubilidade aperfeiçoadas
BR0213037A (pt) Derivados de pirimidina
ES2422081T3 (es) Péptido Ser-Ser-Ser-Arg y sus utilizaciones medicinales
DE60012890D1 (de) Neue guanidin-derivate als zelladhäsion-inhibitoren
BR0317027A (pt) Derivados de (2-amino-fenil)-amida de ácido arlileno-carboxìlico como agentes farmacêuticos
TW200519101A (en) Benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors
BR0113165A (pt) Derivados de 4-pirimidinamina, composições farmacêuticas e métodos relacionados
BR0012327A (pt) Pirrolidinas e piperidinas neurotróficas, e composições e métodos relacionados
BR0311642A (pt) Formulação de divalproex de sódio de liberação aumentada
EP0861663A3 (en) Osteoclastgenic inhibitory agent comprising interleukin-18
MXPA05006889A (es) Compuestos aromaticos como agentes anti-inflamatorios, inmunomoduladores y anti-proliferativos.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 23/02/2016, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/08/2002 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 13/08/2022